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INTRODUCTION
Indonesia is the fourth most populated country in
the world with a considerably high population
growth rate. Based on the Central Agency on Sta-
tistics, the population of Indonesia in 2010 is
237,641,326 people, meaning an increase of
31,373,731 people since year 2000. The population
growth rate of Indonesia from 2000 to 2010 ap-
proximated 1.49% per year, which means that if
family planning programs are not reinforced, the
population of Indonesia is predicted to reach 368
million people by year 2020.1
Currently, the most commonly used contracep-
tive method is hormonal contraceptive methods,
which includes depot medroxyprogesterone ace-
tate (DMPA) injection, combined injectable contra-
ceptives and subcutaneous contraceptive im-
plants.2
DMPA is a synthetic progesterone that has simi-
lar chemical structure to progesterone that has glu-
cocorticoid properties, while levonorgestrel im-
plants have mineralocorticoid properties. This
means that theoretically these contraceptive me-
thods could cause an increase in body weight.3
Abstract
Objective: To determine the comparison of body mass index (BMI)
among acceptors of injectable depot medroxyprogesterone acetate
(DMPA) with levonorgestrel implant acceptors for 1 year and com-
parison of lipid profiles between depot medroxyprogesterone ace-
tate acceptors with levonorgestrel implants for 1 year.
Method: This study was conducted at dr. Wahidin Sudirohusodo
hospital, Makassar and its satellite hospitals as well as family plan-
ning social service cooperation between the National Family Plan-
ning Coordinating Board with the Department of Obstetrics and Gy-
necology Hasanuddin University.
Result: The results showed the increase in BMI of levonorgestrel im-
plant acceptors (1.25 kg/m2) was greater than DMPA acceptors
(0.74 kg/m2). HDL cholesterol and triglycerides did not change sig-
nificantly in either groups. LDL cholesterol was increased in DMPA
acceptors (9.63 mg/dl) and decreased in implant acceptors (1.62
mg/dl). Total cholesterol increased in DMPA acceptors at 8.67
mg/dl) while in the levonorgestrel implant acceptors it was de-
creased by 5.37 mg/dl.
Conclusion: Weight gain occured among acceptors of DMPA and im-
plant however the weight gain is more profound among the implant
acceptors.
[Indones J Obstet Gynecol 2014; 3: 121-126]
Keywords: body mass index, DMPA, levonorgestrel implant, lipid
profile
Abstrak
Tujuan: Untuk mengetahui perbandingan indeks massa tubuh (IMT)
antara akseptor KB suntik depot medroksiprogesteron asetat (DMPA)
dengan akseptor implan levonorgestrel selama 1 tahun serta perban-
dingan profil lipid antara akseptor depot medroksiprogesteron asetat
dengan implan levonorgestrel selama 1 tahun.
Metode: Penelitian ini dilaksanakan di rumah sakit pendidikan
dr.Wahidin Sudirohusodo Makassar dan jejaring serta safari KB ker-
jasama antara Badan Koordinasi Keluarga Berencana Nasional de-
ngan Bagian Obstetri dan Ginekologi Universitas Hasanuddin.
Hasil: Penelitian menunjukkan peningkatan IMT akseptor implan
levonorgestrel (1,25 kg/m2) lebih besar dibanding akseptor DMPA (0,74
kg/m2). Kolesterol HDL dan trigliserida tidak mengalami perubahan
yang bermakna pada kedua kelompok akseptor. Kolesterol LDL me-
ngalami peningkatan pada akseptor DMPA (9,63 mg/dl) dan penurunan
pada akseptor implan (1,62 mg/dl). Kolesterol total meningkat pada ak-
septor DMPA sebesar 8,67 mg/dl sedang pada akseptor implan levonor-
gestrel mengalami penurunan sebesar 5,37 mg/dl.
Kesimpulan: Peningkatan berat badan terjadi pada akseptor DMPA
dan implan namun peningkatan berat badan lebih besar pada aksep-
tor implan.
[Maj Obstet Ginekol Indones 2014; 3: 121-126]
Kata kunci: DMPA, implan levonorgestrel, indeks massa tubuh, profil
lipid
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A previous study by Fraser and Dennerstein re-
ported weight gain in DMPA acceptors. However,
a comparative study on long-term DMPA use by
Surasak Taneepanichskul et al concludes that no
significant difference in weight gain is observed
between DMPA users and controls.4
Weight changes in implant acceptors have been
reported by several clinical trials affirming that im-
plant acceptors in America with 1-year period of
utilization experienced weight gain at an average
of 1.2 pounds.
From the stated theoretical framework and pre-
vious studies, we find it necessary to do a study on
the BMI changes in DMPA acceptors in comparison
with implant acceptors.
METHODS
This study is carried out at Dr. Wahidin Sudiro-
husodo Hospital and several teaching hospitals in
Makassar, as well as participants of mobile family
planning services provided by the National Family
Planning Coordinating Board in collaboration with
the Obstetrics and Gynecology Department Hasa-
nuddin University. The duration of the study spans
from December 2011 until December 2012.
We performed a prospective comparative obser-
vation by comparing BMI and lipid profiles in
DMPA injection acceptors and levonorgestrel im-
plant acceptors. The sample in this study is women
accepting DMPA contraceptives or levonorgestrel
implants who subsequently had quarterly weight
and height measurement as well as blood sample
collection for a period of one year.
The population we target in this study are ac-
ceptors of injectable DMPA contraceptives and
levonorgestrel implants in the family planning
clinic of teaching hospitals in Makassar as well as
the mobile family planning program. The inclusion
criteria is women accepting injectable DMPA con-
traceptives or 2-capsule levonorgestrel implant
who have signed the informed consent.
The data collected was analyzed using bivariate
analysis in the form of independent and "before/af-
ter" t-test to test the average from two populations
that are independent of each other and which the
researcher has no information on the variability of
the population. Independent means that one popu-
lation is not influenced by or related to the other
population.
RESULTS
In Table 1 we can see that the age of DMPA and
implant acceptors ranged between 20-35 years old
with most DMPA acceptors falling in the age range
of 30-34 years old (13 people; 61.9%) and for im-
plant acceptors most fall into the age range of 20-
24 years old (9 people; 81.8%).
Table 1. Baseline Characteristics of DMPA and Implant
Acceptors.
Total
No Characteristic DMPA Implant
N % N %
1 Age (years)
 20-24 2 18.2% 9 81.8%
 25-29 6 50.0% 6 50.0%
 30-34 13 61.9% 8 38.1%
 35 3 75.0% 1 25.0%
2 Education Level
 Elementary 9 64.3% 5 35.7%
 Junior high school 9 50.0% 9 50.0%
 Senior high school 6 37.5% 10 62.5%
3 Occupation
 Private employee 2 100.0% 0 0.0%
 Housewife 22 47.8% 24 52.2%
Regarding education levels, DMPA acceptors
were dominated by samples with elementary
school education (9 people; 64.3%) and junior high
school education (9 people; 50%) while implant ac-
ceptors were dominated by samples with senior
high school education (10 people; 62.5%). For oc-
cupational status, almost all of our samples were
housewives, while only two were private sector
employees.
Table 2 illustrated the change in BMI experi-
enced by the 24 DMPA acceptors as measured
quarterly. At month 0, the average weight of DMPA
acceptors was 55.15 kg with average BMI of 22.76
kg/m2 with a drop in weight at the third month of
0.16 kg with BMI of 22.70 kg/m2. Starting from
month 6, DMPA acceptors experienced an increase
in weight and BMI. Furthermore, at month 9 they
experienced a significant gain in weight (p=0.014)
and BMI (p=0.010). In general, comparing month
0 to month 12 in DMPA acceptors, there was a sig-
nificant gain in body weight (p=0.001) and BMI
(p=0.000).
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Furthermore, Table 2 also shows that at the first
measurement, the average body weight of implant
acceptors was 49.98 kg with average BMI of 21.31
kg/m2 and there was a significant gain in body
weight (p=0.008) and BMI (p=0.005). Comparing
the first and last measurements in implant ac-
ceptors, there was a significant increase of body
weight averaging 2.92 kg (p=0.002) with an aver-
age BMI of 22.29 kg/m2 (p=0.001).
Table 3 shows that average HDL levels of DMPA
acceptors was 47.29 mg/dl at the first month,
which was within normal levels (>40 mg/dl). On
the third month, there was a rise in HDL levels of
3.37 mg/dl although it was insignificant. On the 6th
and 9th month, HDL levels show a tendency to de-
cline which continues until the level reach 46.29
mg/dl on the last measurement.
Likewise, average HDL levels in implant ac-
ceptors were within normal limits. On the third
month, HDL level was reduced by 1.63 mg/dl but
was continued by a rise starting from month 6 to
the end of the study. However, this change in HDL
level was found to be insignificant.
Average LDL level in DMPA acceptors on the
first measurement was 117.37 mg/dl, which was
higher than the normal level of 100 mg/dl. On the
third month, average LDL level fell by 3.87 mg/dl
but increased on the sixth month and showed to
be steady until the 12th month.
Among implant acceptors, LDL levels on first
measurement averaged 112.62 mg/dl. On the third
and sixth month, the trend was found to be increas-
ing but fell on the 9th and last month. The changes
in LDL among DMPA and implant acceptors
showed a significant rise on month 12 with
p=0.028.
Furthermore, triglyceride levels in DMPA ac-
ceptors were found to be within normal limits
(<150 mg/dl). On the first measurement, trigly-
ceride level was 121.67 mg/dl and showed a down-
ward trend until the 9th month but experienced a
climb on the last month. This change in triglyceride
level did not reach statistical significance. The ave-
rage triglyceride level of implant acceptors on the
first measurement was within normal limits
(122.25 mg/dl). The fluctuation in triglyceride
level in implant acceptors was similar to DMPA ac-
ceptors. However, the rise in triglyceride level in
the last month did not surpass the measurement
in month 0.
Total cholesterol levels at month 0 in both
groups were within normal levels (<200 mg/dl). In
DMPA acceptors, total cholesterol experienced a
rise starting from the 6th month with a total in-
crease of 8.67 mg/dl in total cholesterol. However,
the increase was not found to be statistically sig-
nificant. In contrast, average total cholesterol
showed a tendency to decrease until the final
measurement although a spike of 5.13 mg/dl was
Table 2. Quarterly BMI Changes in DMPA and Implant Acceptors in a One Year Period.
Mean
Month DMPA (N=24) Implant (N=24)
weight (kg) p BMI p weight (kg) p BMI p
0 55.15 22.76 49.98 21.31
0.517 0.587 0.395 0.299
3 54.99 22.70 50.34 21.49
0.073 0.077 0.179 0.116
6 55.71 22.99 50.93 21.61
0.014 0.010 0.008 0.005
9 56.23 23.20 52.24 22.29
0.001 0.000 0.002 0.001
12 56.94 23.50 52.90 22.56
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observed at month 6. On the last month, the drop
in total cholesterol was 5.37 mg/dl in comparison
with the first month. The difference in total choles-
terol change between DMPA and implant acceptors
was found to be statistically significant (p=0.035).
DISCUSSION
This study shows that the increase in body weight
and BMI was more pronounced in implant ac-
ceptors compared to DMPA acceptors. We hy-
pothesize this is caused by the mineralocorticoid
properties of levonorgestrel, leading to fluid reten-
tion. However, further studies are needed to inves-
tigate the effect of levonorgestrel on weight
changes until the end of implant use. Other factors
that may influence weight gain but were not stu-
died include genetic patterns, psychologic factors,
physical activity, eating habits, alcohol consump-
tion and smoking. Some people have a habit of eat-
ing more as a response mechanism towards nega-
tive psychological conditions such as sadness,
boredom or anger. However, some others have the
opposite response. Aside from the factors listed
previously, specific medical conditions or medica-
tions may cause weight gain.5
A study by Marcia Pantoja et al found an in-
crease of BMI as much as 1.78 kg/m2 in DMPA ac-
ceptors after 1 year of usage. Another study re-
ported 5% increase in body weight after 6 month
usage of DMPA or a monthly increase of approxi-
mately 0.35 kg. A study by Balogun in Nigeria
showed the increase of body weight in levonorges-
trel contraceptive implant acceptors is 1.3 kg and
2.4 kg in the 6th and 12th month after implant use
respectively.6,7
HDL cholesterol has protective effects from
coronary disease. High HDL levels can be found in
individuals who are physically active and not
obese.8 In this study, HDL levels in DMPA acceptors
fell starting from the 6th month until the end of the
study, with a total decrease of 1 mg/dl from the
first measurement. In implant acceptors, HDL le-
vels declined on the third month, but increased in
the following months. In the final measurement, to-
tal HDL levels underwent a decrease of 0.46 mg/dl
compared to the first measurement. However, the
changes in HDL levels in DMPA or implant ac-
ceptors were not found to be statistically signifi-
cant.
Levonorgestrel concentration in the blood is ap-
proximately 80  g/24 hours after implant insertion
which persists until the 6th month and declined to
30  r/24 hours thereafter. HDL was found to in-
crease starting from the 6th month in accordance
to the fall in levonorgestrel concentration in blood.
LDL cholesterol is a lipoprotein responsible for
transporting serum cholesterol into the cells. This
function of LDL allows it to mark the development
of cardiovascular diseases, such as coronary heart
disease.9
In DMPA acceptors, the rise in LDL until the 12th
month was 6.5 mg/dl from the first measurement.
In implant acceptors, LDL level was elevated to a
maximum level on the 9th month but fell until the
12th month so that it had an overall reduction of
1.62 mg/dl from the first month. The change in LDL
was significantly different in DMPA and implant ac-
ceptors (p=0.028), which indicates the tendency of
DMPA acceptors to experience a rise in LDL levels
in the long term compared to implant acceptors.
Table 3. Quarterly Change in HDL, LDL, Triglyceride and Total Cholesterol in DMPA and Implant Acceptors.
Mean (mg/dl)
Month HDL LDL Triglyceride Total cholesterol
DMPA Implant p DMPA Implant p DMPA Implant p DMPA Implant p
0 47.29 50.54 0.265 117.37 112.62 0.580 121.67 122.25 0.806 183.70 181.37 0.820
3 50.66 48.91 0.756 113.50 116.79 0.680 120.96 111.50 0.805 184.17 180.12 0.652
6 48.41 51.66 0.357 121.62 119.67 0.795 116.46 110.45 0.993 193.41 186.50 0.493
9 48.08 51.42 0.370 128.79 114.46 0.062 101.79 92.83 0.655 188.54 178.79 0.239
12 46.29 51.00 0.142 127.00 111.00 0.028 112.33 107.33 0.481 192.37 176.00 0.035
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LDL reached its maximum level faster in implant
acceptors, which was at week six. We hypothesize
that this is coupled with the concentration of
levonorgestrel, which was highest in the 6th month
with subsequent decline until the 12th month. In
DMPA acceptors, the concentration of medroxy-
progesterone acetate tends to be stable causing
constant suppression of endogenous estrogen. En-
dogenous estrogen suppression by progestin cau-
ses an increase in the excretion of VLDL in the liver.
LPL will subsequently mediate the lipolysis of
VLDL into VLDL remnant or commonly known as
IDL. Hepatic lipase activity will convert IDL into
LDL. The consequence of this chain of events is the
increase of LDL concentration in the blood.
Carrie et al found no significant change of LDL
levels in DMPA acceptors. In contrast, Araujo et al
reported a slight decrease in LDL concentration in
the first year of levonorgestrel implant use.9
Previously, the role of triglycerides is often ne-
glected but current evidence shows the contribu-
tion of triglycerides on the pathogenesis of coro-
nary heart disease. In our study, the triglyceride
levels in DMPA acceptors shows a tendency of de-
creasing. The maximum drop in triglyceride con-
centration was found in the 9th month at 92.83
mg/dl. Both DMPA and implant acceptors experi-
ence the greatest decline on month 9. Although this
fall in triglyceride concentration was found in more
implant acceptors, it was not found to be statisti-
cally significant.
Triglyceride concentration reduction was less
pronounced in implant acceptors than DMPA ac-
ceptors, which may be caused by the younger age
of the implant group. With addition of age, physical
activity tend to decrease leading to a decline in me-
tabolic rate. Consequently, triglyceride levels tend
to increase with age.8 Another factor influencing
triglyceride level is diet and eating habits, even-
though it was not investigated in this study.
Kaunitz et al did not find a significant change in
triglyceride level in DMPA acceptors after 96
weeks of use.10
Total cholesterol level of DMPA acceptors was
183.7 mg/dl on the first measurement and the
trend seems to be increasing on the following
month. On the final measurement, the rise in total
cholesterol level was as much as 8.67 mg/dl. Im-
plant acceptors started with a total cholesterol of
181.37 mg/dl and reached its maximum level on
month 6. After that, total cholesterol tend to fall
until the 12th month with a total drop of 5.37
mg/dl. We can see a significant difference in overall
total cholesterol changes between DMPA and im-
plant acceptors (p=0.035).
Theoretically, the total cholesterol increase in
DMPA and implant acceptors was caused by induc-
tion of pre-adipocyte differentiation, LPL activity
and triglyceride synthesis, which increase visceral
adipose.11
CONCLUSION
Both DMPA and implant acceptors experience an
increase in BMI, but it was more pronounced in
implant acceptors. HDL reduction occurred in both
contraceptive methods but in implant acceptors it
only occurred in the third month and bounced back
until the last month. LDL concentration in DMPA
acceptors increased until month 12, while in im-
plant acceptors it increased until month 9 before
falling at the last measurement. Triglyceride con-
centration showed a non-significant decrease in
both groups. Total cholesterol showed an increas-
ing trend in DMPA acceptors which was observed
until the last measurement. Meanwhile, in implant
acceptors, the rise in cholesterol was only observed
until the 6th month and continued to fall for the
following months.
Further investigation is needed on the weight
and lipid profile changes in DMPA and implant ac-
ceptors until the end of effective contraceptive du-
ration. Investigation on other hormonal contracep-
tive methods is also needed to increase the know-
ledge of clinicians involved in family planning.
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